29 June 2023 -  Endo International announced today that Paladin Labs, an Endo operating company, received Health Canada's approval of Xcopri (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.

Paladin Labs expects to launch Xcopri in December 2023.

Read Endo Pharmaceuticals press release